Interleukin Genetics, Inc - ILIU - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: May 19, 2013

Interleukin Genetics, Inc - SIC # 8071

Ticker	Exchange	SIC #	Website	Latest Ticker
ILIU	Over the counter	8071	http://www.ilgenetics.com	0.38 -0.10
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for Interleukin Genetics, Inc INTERLEUKIN GENETICS INC Financials - May 21st, 2013 11:04 am Interleukin Genetics, Inc. Announces Conference Call to Discuss First Quarter 2013 Results - May 20th, 2013 10:00 am Interleukin Genetics Announces $12 Million Private Placement - May 20th, 2013 5:55 am INTERLEUKIN GENETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity - May 19th, 2013 11:27 pm PST Manuscript Submitted, Awaiting Publication Acceptance - May 17th, 2013 12:00 pm Interleukin Genetics Reports First Quarter 2013 Financial Results - May 14th, 2013 2:30 pm INTERLEUKIN GENETICS INC Files SEC form 10-Q, Quarterly Report - May 14th, 2013 7:07 am Interleukin Genetics and University of North Carolina Publish Genetic Factors Predictive of Progression of Knee Osteoarthritis - May 8th, 2013 6:35 am PST Closer To Commercialization - Apr 1st, 2013 4:00 am Interleukin Genetics Reports Fourth Quarter and Year End 2012 Financial Results - Mar 28th, 2013 2:20 pm INTERLEUKIN GENETICS INC Files SEC form 8-K, Change in Directors or Principal Officers - Mar 28th, 2013 7:04 am INTERLEUKIN GENETICS INC Files SEC form 10-K, Annual Report - Mar 28th, 2013 7:03 am Interleukin Genetics, Inc. Announces Conference Call To Discuss Fourth Quarter 2012 Results - Mar 22nd, 2013 5:16 am Interleukin Genetics, Inc. Announces Conference Call to Discuss Fourth Quarter 2012 Results - Mar 21st, 2013 2:20 pm Interleukin Genetics and Renaissance Health Service Corporation Enter into a Preferred Participation Agreement for PST® Genetic Test - Mar 4th, 2013 2:56 pm Initial Agreement With Renaissance Health - Mar 4th, 2013 1:41 pm INTERLEUKIN GENETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement - Mar 1st, 2013 2:05 pm INTERLEUKIN GENETICS INC Files SEC form 8-K, Other Events - Jan 3rd, 2013 3:17 pm Interleukin Genetics Appoints Scott Snyder as Chief Marketing Officer - Jan 3rd, 2013 2:10 pm INTERLEUKIN GENETICS INC Files SEC form 8-K, Change in Directors or Principal Officers - Dec 26th, 2012 4:05 am View All Current Headlines >>